Back to Mesothelioma News

MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States

October 25, 2011
Back to Mesothelioma News Center

MILAN, ITALY-- - MolMed S.p.A. announces the expansion in the United States of a pivotal Phase III trial of its investigational anticancer drug NGR-hTNF in malignant pleural mesothelioma, with treatment ...


Read the full story: MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United States

Mesothelioma
Lawsuit Evaluation

First Name
Last Name
Phone Number
Email
Zip Code
Details:
Please Include Diagnosis Date
Type The Number Below: